Compensation award — excluded from discretionary-purchase analysis.
Traded Nov 7, 2025 · Filed Nov 10, 2025
Idexx Laboratories's Executive Vice President sold $3.59M of Idexx Laboratories shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,591,059
Shares × reported transaction price
4 days after results of Nov 3, 2025, 87 days before results of Feb 2, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $708.45 on Nov 7, 2025, within 2% of its 52-week high, after a 12% rise over the previous 30 trading days
52-week range $361.04 (Apr 8, 2025) to $722.94 (Nov 3, 2025), 96% of the way up, from 250 adjusted closes. 30 trading days earlier: $632.22 on Sep 26, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -5.9% | -3.4% | -2.6% |
| 30 days | -0.7% | +0.9% | -1.6% |
| 90 days | -10.2% | +1.6% | -11.8% |
| 180 days | -25.3% | +8.2% | -33.6% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.